BH3-MIMETIC TREATMENT REVEALS SUBTYPE-SPECIFIC BCL-2 PROTEIN DEPENDENCY IN PEDIATRIC MDS WITH EXCESS BLASTS

Sheila Bohler(University Medical Center Freiburg), Miriam Erlacher(University Medical Center Freiburg), Kaan Boztuǧ(Forschungszentrum Jülich), Ben Haladik(Austrian Academy of Sciences), Michael Dworzak(St. Anna Children's Cancer Research Institute), Nastassja K. Scheidegger(University of Zurich), Charlotte M. Niemeyer(University Medical Center Freiburg), Markus Schmugge(University Children's Hospital Zurich), Ayami Yoshimi Nöllke(University Medical Center Freiburg), Beat Bornhäuser(University Children's Hospital Zurich)
EJC Paediatric Oncology
November 5, 2025
10.1016/j.ejcped.2025.100355
Cited by 0

Related Papers

Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
|Journal of Clinical Oncology|2015|383
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
|Blood|2009|347
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
|Leukemia|2009|338
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
|Journal of Clinical Investigation|2010|311